EXAS Exact Sciences Corp

Price (delayed)

$98.96

Market cap

$17.02B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.52

Enterprise value

$19.03B

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights
EXAS's gross profit has surged by 52% year-on-year and by 11% since the previous quarter
EXAS's revenue has surged by 51% year-on-year and by 11% since the previous quarter
The company's equity rose by 42% YoY but it fell by 2.5% QoQ
The company's quick ratio has shrunk by 64% YoY and by 13% QoQ
The company's debt rose by 40% YoY

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
171.95M
Market cap
$17.02B
Enterprise value
$19.03B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.77
Price to sales (P/S)
9.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.12
Earnings
Revenue
$1.71B
EBIT
-$1.05B
EBITDA
-$859.66M
Free cash flow
$87.89M
Per share
EPS
-$5.52
Free cash flow per share
$0.51
Book value per share
$20.75
Revenue per share
$9.98
TBVPS
$13.95
Balance sheet
Total assets
$6.72B
Total liabilities
$3.17B
Debt
$2.38B
Equity
$3.56B
Working capital
$993.51M
Liquidity
Debt to equity
0.67
Current ratio
2.47
Quick ratio
2.27
Net debt/EBITDA
-2.35
Margins
EBITDA margin
-50.2%
Gross margin
75.5%
Net margin
-50.5%
Operating margin
-63.7%
Efficiency
Return on assets
-15.2%
Return on equity
-29.4%
Return on invested capital
-32.9%
Return on capital employed
-17.4%
Return on sales
-61.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
1.24%
1 week
5.62%
1 month
-5.44%
1 year
-3.57%
YTD
-25.31%
QTD
3.68%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$1.71B
Gross profit
$1.29B
Operating income
-$1.09B
Net income
-$864.77M
Gross margin
75.5%
Net margin
-50.5%
The operating margin has dropped by 156% year-on-year
EXAS's gross profit has surged by 52% year-on-year and by 11% since the previous quarter
EXAS's revenue has surged by 51% year-on-year and by 11% since the previous quarter
The company's net income fell by 14% QoQ

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
4.77
P/S
9.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.12
Exact Sciences's EPS has decreased by 12% from the previous quarter
The stock's price to book (P/B) is 48% less than its 5-year quarterly average of 9.2 and 31% less than its last 4 quarters average of 6.9
The company's equity rose by 42% YoY but it fell by 2.5% QoQ
EXAS's revenue has surged by 51% year-on-year and by 11% since the previous quarter
EXAS's price to sales (P/S) is 43% less than its 5-year quarterly average of 17.4 and 24% less than its last 4 quarters average of 13.0

Efficiency

How efficient is Exact Sciences business performance
Exact Sciences's ROS has plunged by 162% YoY
The company's return on invested capital has shrunk by 161% YoY and by 3.8% QoQ
The ROE has contracted by 4.3% from the previous quarter
EXAS's return on assets is down by 2.7% since the previous quarter

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 112% more than the total liabilities
The company's quick ratio has shrunk by 64% YoY and by 13% QoQ
EXAS's current ratio has shrunk by 64% YoY and by 12% QoQ
The company's debt is 33% lower than its equity
The company's equity rose by 42% YoY but it fell by 2.5% QoQ
The company's debt rose by 40% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.